Albumin was associated with a small reduction in all-cause mortality when compared to an alternative resuscitation fluid in patients with septic shock (RR: 0.89, 95% CI: 0.80, 0.99; p = 0.04) [20], [21], [23]; however, this mortality benefit became insignificant when the comparison was limited to patients with sepsis [22], [37] and severe sepsis [13], [21], [24], [25], [27]–[29]. This evidence concerns the gene ALB and Shock.